Ditching the Beta: A CFO’s Perspective on How Glassbury AI De-Risks Alzheimer’s Clinical Trials and Stabilizes the Cost of Capital

The contemporary biopharmaceutical ecosystem is currently navigating a profound systemic productivity crisis, frequently contextualized by "Eroom’s Law," wherein the cost of bringing a single novel therapeutic to market has surged exponentially to between $800 million and $1.4 billion.